Mogamulizumab (sponsor: Kyowa-Kirin) was approved this week for use in Cutaneous T-Cell Lymphoma (CTCL) for patients who received 1 prior line of therapy. Stanford’s multi-disciplinary Cutaneous Lymphoma team (PI: Dr. Youn Kim) as the lead site for this study had a successful FDA inspection in December 2017, paving the way for its accelerated approval.

Hats off to the hard work of all the members of this team.